Study reports 33-fold rise in new BPC-157 users since 2020
The unapproved peptide, publicly backed by Health Secretary Robert F. Kennedy Jr., is often sold with TB-500 in what sellers call a "Wolverine stack."
PR
By Priya Raman · Science Reporter
Sep 16 09:38 ETSource: MedPage Today
The wire
- 01New users of BPC-157 rose 33-fold from 2020 to 2026, according to a study reported by Reuters and rounded up by MedPage Today.
- 02BPC-157 is unapproved and widely sold for pain relief and healing, frequently paired with TB-500, so clinicians should expect more patients arriving already using it.
- 03The roundup item does not give the study's data source, cohort size or method, and the peptide's regulatory status in the US remains unchanged.
From the source
Read at medpagetoday.comJudge Halts Trump Plan; RFK Jr.'s 'Wolverine' Peptide; Swapping Nurses for AI
— Health news and commentary gathered by MedPage Today staff